The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The 2022 Tandem Meetings | Approval of axi-cel in second-line for R/R LBCL & label update
Evandro Bezerra, MD, Mayo Clinic, Rochester, MN, gives an update on the use of axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL). In January 2022, the FDA approved a new label update for axi-cel allowing the use of prophylactic dexamethasone to limit CAR-T toxicity. In addition, following the positive results of the ZUMA-7 (NCT03391466) and TRANSFORM (NCT03575351) trials, the FDA approved axi-cel in patients with primary refractory disease in April 2022. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
